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Nucleic acid-based aptamers have been developed for the specific delivery of diagnostic nanoprobes. Here, we
introduce a new class of smart imaging nanoprobe, which is based on hybridization of a magnetic nanocrystal
with a specific aptamer for specific detection of the angiogenic vasculature of glioblastoma via magnetic resonance
(MR) imaging. The magnetic nanocrystal imaging core was synthesized using the thermal decomposition method
and enveloped by carboxyl polysorbate 80 for water solubilization and conjugation of the targeting moiety.
Subsequently, the surface of the carboxylated magnetic nanocrystal was modified with amine-functionalized
aptamers that specifically bind to the vascular growth factor receptor 2 (VEGFR2) that is overexpressed on
angiogenic vessels. To assess the targeted imaging potential of the aptamer-conjugated magnetic nanocrystal for
VEGFR2 markers, the magnetic properties and MR imaging sensitivity were investigated using the orthotopic
glioblastoma mouse model. In in vivo tests, the aptamer-conjugated magnetic nanocrystal effectively targeted
VEGFR2 and demonstrated excellent MR imaging sensitivity with no cytotoxicity.
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Magnetic resonance (MR) imaging is a superior mole-
cular imaging technique for clinical diagnosis of cancer
because it provides noninvasive tomographic imaging
with high spatial resolution [1,2]. The sensitivity of MR
imaging has significantly improved in recent years by
using magnetic nanocrystal (MNC) because an enhanced
T2 shortening effect is ascribed to the high crystallinity
of MNC [3-5]. In particular, the immobilization of a
targeting moiety on the magnetic nanocrystal has facili-
tated biomarker-specific molecular imaging by MR [6].
Thus, biomarker-specific molecular imaging for cancer
enables early and specific detection of cancer cells and
facilitates analysis of disease progression to improve the
survival rate of cancer patients [7,8].* Correspondence: ymhuh@yuhs.ac; haam@yonsei.ac.kr
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in any medium, provided the original work is pGlioblastoma is the most common and lethal intracra-
nial tumor. This brain cancer exhibits a relentless malig-
nant progression with characteristics of widespread
invasion, destruction of normal brain tissue, resistance to
conventional therapeutic approaches, and certain death.
In addition, glioblastoma is among the most highly vascu-
lar of all solid tumors. Although there are marked
genomic differences between primary (de novo pathway)
and secondary (progressive pathway) glioblastoma, a
physiological adaptation to hypoxia and critical genetic
mutations commonly converge on a final tumor angiogen-
esis pathway. Therefore, precise molecular imaging of
glioblastoma can be a crucial step for effective treatment
[9,10]. Recent studies have identified key angiogenic fac-
tors, such as basic fibroblast growth factor, interleukin-8,
hypoxia-inducible factors, and vascular endothelial growth
factor A (VEGFA). Among these, VEGFA and one of its
receptors (vascular endothelial growth factor receptor 2,
VEGFR2) have been established as the primary proan-
giogenic factors [11,12].Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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imaging probe to enable precise recognition of angio-
genic vasculature of glioblastoma. To synthesize a sensi-
tive MR imaging contrast agent, monodispersed MNC
(Fe3O4) with high crystallinity was synthesized by ther-
mal decomposition method and subsequently enveloped
with tri-armed carboxyl polysorbate 80 by a nanoemul-
sion method. To prepare the magnetic nanoprobe for
specific binding with VEGFR2 on angiogenic vessels,
VEGFR2-specific aptamers (Apt) based on nucleic acid
were immobilized on the surface of carboxylated MNC.
Recently, Apt based on single-stranded nucleic acid
molecules have been developed as a targeting moiety
due to their high affinity and selectivity for a variety of
chemical and biological molecules [13]. The main advan-
tage of Apt over antibody lies in the relative ease with
which they can be selected for analysis of any target and
their stability against biodegradation and denaturation
[14]. The chemical structure and colloidal size of
aptamer-modified MNC (Apt-MNC) were evaluated. To
assess the molecular imaging potential of Apt-MNC, weFigure 1 Schematic illustration of the preparation steps for VEGFR2-s
preparation steps for VEGFR2-specific magnetic nanoprobe and applicationinvestigated MR imaging sensitivity and binding affinity
for angiogenic vessels expressing VEGFR2 using the
orthotopic glioblastoma mouse model. A conceptual
schematic illustration is provided in Figure 1.
Methods
Materials
Iron (III) acetylacetonate, 1,2-hexadecanediol, oleic acid,
oleylamine, benzyl ether, polysorbate 80, succinic an-
hydride, 4-dimethylaminopyridine, triethylamine, and
1,4-dioxane were purchased from Sigma-Aldrich. The
anti-VEGFR2 DNA aptamer [51-mer sequence: H2N-
C6-5′-d(ACGAGCZACG ACGZCZGGZG ZAAZZZAZ
AA AGACACZGZG ZAZAZCA ACAA)-3′; Z is 5-
N-(benzylcarboxyamide)-2′-deoxyuridine (BzdU), with
MW 17,567.05 Da] can target VEGFR2. This anti-
VEGFR2 DNA aptamer (Cat number 186, Kd = 0.12 nM)
was kindly provided by Aptamer Science, Inc. (http://www.
aptsci.com/product/product.tml). Phosphate-buffered sa-
line (PBS; 10 mM, pH 7.4), Dulbecco's modified Eagle
medium (DMEM), and minimal essential medium (MEM)pecific magnetic nanoprobe. Schematic illustration of the
for MR imaging of angiogenic vasculature from glioblastoma.
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poration, Carlsbad, CA, USA). All other chemicals and
reagents were analytical grade and obtained from Sigma-
Aldrich (St. Louis, MO, USA).
Synthesis of carboxylated magnetic nanocrystal
As described previously, we synthesized monodispersed
MNC by the thermal decomposition method. In detail, 2
mmol of iron (III) acetylacetonate, 10 mmol of 1,2-
hexadecanediol, 6 mmol of oleic acid, and 6 mmol of
oleylamine were dissolved in 20 mL of benzyl ether in
an ambient nitrogen atmosphere. The mixture was pre-
heated to 200°C for 2 h and refluxed at 300°C for 30
min. The resulting solution containing MNC was cooled
to room temperature, and MNC was purified with an
excess of pure ethanol. The synthesized MNC was
grown to a size of 12 nm by a seed-mediated growth
method [15]. To immobilize VEGFR2-specifc aptamers
on MNC, carboxylated MNC was fabricated using
tri-armed carboxyl polysorbate 80 by a nanoemulsion
method. Here, the terminal group of polysorbate 80 was
modified with carboxyl group using succinic anhydride
to provide the conjugation site for aminated aptamers
[16], by adding 4 mL of n-hexane containing 10 mg of
MNC to 20 mL deionized water containing 100 mg
carboxyl polysorbate 80. After mutual saturation of the
organic and aqueous phases, the mixture was sonicated
for 20 min at 190 W with vigorous stirring. After the
sonication, the organic solvent was evaporated rapidly
using a rotary evaporator to form carboxylated MNC,
and free molecules were removed using a centrifugal
filter (Centriprep YM-3, 3,000 Da cutoff, Amicon,
Millipore, Billerica, MA, USA) [17].
Preparation of VEGFR2-targetable aptamer-conjugated
magnetic nanoprobe
VEGFR2-specific aptamers were conjugated with
carboxylated MNC for specific imaging of VEGFR2 in
glioblastoma tumors via MR imaging. In detail, 38 μmol of
1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide, 38 μmol
of sulfo-N-hydroxysuccinimide, and 11 nmol of aptamers
were added to 10 mg of carboxylated MNC suspended in
5 mL of nuclease-free water. After the reaction at 4°C for
24 h, Apt-MNC was purified with an ultracentrifugal filter
(Amicon Ultra; Millipore, Billerica, MA, USA) to remove
side-products [18].
Characterization of Apt-MNC
The characteristic bands for polysorbate 80 and carboxyl
polysorbate 80 were analyzed using Fourier transform
infrared (FTIR) spectroscopy (Excalibur Series, Varian,
Inc., Palo Alto, CA, USA). The size and morphology of
Apt-MNC were investigated using transmission electron
microscopy (TEM, JEM-2100 LAB6, JEOL Ltd., Akishima,Tokyo, Japan). The hydrodynamic diameter and surface
charge of carboxylated MNC and Apt-MNC were mea-
sured using laser scattering (ELSZ, Otsuka Electronics,
Hirakata, Osaka, Japan). The magnetic hysteresis loop and
the saturation magnetization of Apt-MNC were measured
in dried sample at room temperature using a vibrating
sample magnetometer (model-7300, Lake Shore Cryoto-
nics Inc., Westerville, OH, USA). The T2-weighted MR
imaging of Apt-MNC solution was obtained using a 1.5-T
clinical MR imaging instrument with a micro-47 surface
coil (Intera, Philips Medical Systems, Andover, MA, USA)
with the following parameters: resolution of 234 × 234
mm, section thickness of 2.0 mm, TE = 60 ms, TR = 4,000
ms, and number of acquisitions = 1. In addition, the relax-
ation rate (R2, unit of s−1) for various Fe concentrations of
Apt-MNC was measured at room temperature by the
Carr-Purcell-Meiboom-Gill sequence: TR = 10 s, 32
echoes, 12 ms even echo space, number of acquisitions = 1,
point resolution 156 × 156 μm, and section thickness
0.6 mm.
Biocompatibility tests for Apt-MNC
The cytotoxicity of Apt-MNC for U87MG cells (human
glioblastoma) was evaluated by measuring the inhibition
of cell growth using a 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. U87MG cells
(1.0 × 107 cells) were plated in 96-well plates, incubated
in MEM containing 5% fetal bovine serum and 1% anti-
biotics at 37°C in a humidified atmosphere with 5%
CO2, and treated with carboxylated MNC or Apt-MNC
at various concentrations for 24 h. An MTT assay was
performed and the relative percentage of cell viability
was calculated as the ratio of formazan intensity in cells
treated with carboxylated MNC or Apt-MNC to the
formazan intensity in non-treated cells.
In vitro targeting assay
Sulfo-N-hydroxysuccinimide-modified fluorescein was
purchased from Pierce® (fluorescein labeling kit, product
no. 46100; Pierce Biotechnology, Rockford, IL, USA). To
synthesize Apt-conjugated fluorescein (Apt-fluorescein),
0.067 mg of sulfo-N-hydroxysuccinimide-modified fluor-
escein and 0.5 mg Apt were mixed in RNAse-free water
and incubated for 2 h at 4°C. After incubation, the mixture
was purified with an ultracentrifugal filter (Amicon Ultra)
to remove the side-products. We incubated 1.0 mmol of
Apt-fluorescein with VEGFR2-expressing porcine aortic
endothelial cells with overexpressing kinase insert domain
receptor (PAE/KDR) cells (1.0 × 107 cells) for 24 h at
37°C. The fluorescence-stained cells were detached
and washed three times with PBS (pH 7.4, 1 mM). The
cellular binding of Apt was evaluated via flow cytometry
(Caliber, CA, USA) and visualized by confocal microscopy
(LSM 700, Carl Zeiss AG, Oberkochen, Germany).
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VEGFR2 markers, 5.0 × 105 PAE/KDR cells were seeded
and incubated in four-well plates for 2 days at 37°C.
Subsequently, the incubated cells were treated with Apt-
MNC dispersed in DMEM and incubated for an
additional 2 h at 37°C. The PAE/KDR cells treated with
Apt-MNC were collected and washed two times with
PBS. For observations of the attached Apt-MNC to the
target marker, light-scattering images for cells were
recorded using a microscope (Olympus BX51; Olympus
Corporation, Tokyo, Japan) with a high numerical aper-
ture dark-field condenser (U-DCW, Olympus), which
delivers a very narrow beam of white light from a tung-
sten lamp to the surface of the sample. Immersion oil
(nD 1.516, Olympus) was used to narrow the gap between
the condenser and the glass slide and to balance the
refractive index. The dark-field pictures were captured
using an Olympus CCD camera [19].
In vivo MR imaging
To establish the orthotopic brain tumor model, a steril-
ized guide screw was drilled in the skull of BALB/c nude
mouse (4 to 6 weeks old) at an entry site with frontal
lobe ordinates at 2 mm lateral and 1 mm anterior to the
bregma. We implanted 5 × 105 human glioblastoma
U87MG cells suspended in 5 μL 2-[4-(2-hydroxyethyl)Figure 2 Synthesis of Apt-MNC. (a) FTIR spectrum of polysorbate 80 (bla
Apt-MNC (inset: size distribution histogram). (c) Hydrodynamic diameter (bpiperazin-1-yl] ethanesulfonic acid buffer onto the guide
screw after 7 days of bolting. On the seventh day after
implantation, the guide screw was removed and the
incision was sutured. All experiments were conducted
with the approval of the Association for Assessment
and Accreditation of Laboratory Animal Care Inter-
national [20].
MR imaging of the glioblastoma model treated with
carboxylated MNC or Apt-MNC was performed with a
3.0-T MR imaging (Intera, Philips Medical Systems, n = 5).
After intravenous injection into the tail vein using an
insulin syringe (200 μg of Fe/200 μL), we performed
in vivo imaging at various timed intervals. For T2-wieghted
MR imaging, the following parameters were adopted:
resolution of 234 × 234 mm, section thickness of 2.0 mm,
TE = 60 ms, TR = 4,000 ms, and number of acquisitions =
1. Statistical evaluation of data was performed with analysis
of variance test and Student's t test. A p value less than
0.01 was considered statistically significant.
Histological analysis
Hematoxylin and eosin (H & E) staining and Prussian
blue (PB) staining were performed for histological evalu-
ation. The extracted brain tissue from mice injected with
Apt-MNC was dehydrated in increasing alcohol concen-
trations, cleared in xylene, and embedded in paraffin.ck line) and tri-carboxyl polysorbate 80 (blue line). (b) TEM image of
ar) and zeta potential (line scatter) of carboxylated MNC and Apt-MNC.
Figure 3 Properties of Apt-MNC as a contrast agent. (a) Magnetic hysteresis loop of Apt-MNC. (b) T2-weighted images and relaxivity
coefficient (r2) of Apt-MNC.
Figure 4 Cell viabilities of U87MG cells treated with different
concentrations of Apt-MNC and carboxylated MNC.
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slides and were placed twice in a container filled with
hematoxylin for 10 min to stain the nuclei. The tissues
were rinsed in water for 10 min to remove hematoxylin,
the cytoplasm was stained with eosin, and the samples
were dehydrated in the same manner as described above.
After washing three times for 30 min, we added 2 drops
of the mounting solution onto the slide and covered it
with a cover slip. To visualize the extent of Apt-MNC
loading, an additional slide was fixed with 95% alcohol
for 5 min, stained using a solution of 5% potassium
ferrocyanide in 5% HCl (1:1) for 30 min at room
temperature, and rinsed three times in deionized water
to remove the residual staining solution. All tissue
samples were analyzed using a research microscope
(Olympus BX51) and OlyVIA software.
Results and discussion
We synthesized high-quality MNC in terms of size uni-
formity, single crystallinity, and high magnetism, using
the thermal decomposition method, for use as a sensitive
MR imaging contrast agent [3]. The synthesized MNC
exhibited water insolubility due to the presence of
capped fatty acids; thus, this MNC should be modified
using optimal surfactant to ensure its stability in bio-
logical media and biocompatibility in vivo. Here, carb-
oxyl polysorbate 80 was prepared by modifying the
hydroxyl group of polysorbate 80. Succinic anhydride
reacted with the hydroxyl group on polysorbate 80 during
the ring-opening process and the resultant terminal
carboxylate was fabricated. The oxyethylene chains
(-OCH2CH2-) in the carboxyl polysorbate 80 can increase
biocompatibility, and carboxyl groups can be readily con-
jugated with the amine-functionalized targeting moieties
[16]. After the ring-opening esterification reaction of
polysorbate 80, the characteristic peaks of the modified
carboxyl polysorbate 80 were confirmed by FTIR spec-
troscopy. In Figure 2a, polysorbate 80 and tri-carboxyl
polysorbate 80 represented C=O stretching vibration at1,737 cm−1 caused by ester structure (green arrow). How-
ever, the resultant terminal carboxylic acid in tri-carboxyl
polysorbate 80 was confirmed by C=O stretching vibra-
tion at 1,652 cm−1 (red arrow). The dimer structure of
carboxylic acid in a condensed undiluted solution weak-
ened the C=O binding, thus C=O stretching vibration in
carboxylic acid appeared to have a lower wave number
than the C=O stretching vibration in ester.
Subsequently, MNC was coated by nanoemulsion
method using carboxyl polysorbate 80. The nanoscale
emulsions were created by the injection of MNC-laden
organic solvent phase into an aqueous continuous phase
containing carboxyl polysorbate 80 under ultrasonication
and vigorous stirring. The interface of emulsions with
continuum was stabilized by carboxyl polysorbate 80
and MNC within nanoemulsions and was enveloped by
carboxyl polysorbate 80 during a solvent evaporation
Figure 5 In vitro VEGFR2-targeting ability of Apt. (a) Flow cytometry data of porcine aortic endothelial cells with overexpressing kinase insert
domain receptor (PAE/KDR) cells treated with or without Apt-fluorescein. (b) Confocal microscopy images of PAE/KDR cells treated with DAPI
(nucleus, blue) and Apt-fluorescein (cytoplasm, green).
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conjugated with carboxylated MNC to prepare Apt-
MNC for molecular MR imaging of VEGFR2. The
morphology of Apt-MNC was observed by TEM. Uni-
formity and spherical shape of MNC from Apt-MNC
were observed; the average diameter of MNC was 11.7 ±
1.0 nm and clustering of MNC was not observed
(Figure 2b). The hydrodynamic diameter of Apt-MNC
(34.0 ± 5.8 nm) was slightly increased compared withFigure 6 Dark-field microscopy images of PAE/KDR cells. (left panel) Nthat of carboxylated MNC (31.5 ± 2.2 nm) due to Apt
conjugation (Figure 2c). Carboxylated MNC possessed
negative surface charge due to the negatively charged
surface carboxylate in an aqueous phase. Apt-MNC
showed a slightly changed surface charge of −17.0 ± 0.5
mV after Apt conjugation (Figure 2c). These data
indicate that Apt was successfully conjugated with car-
boxylated MNC and Apt-MNC was well dispersed in an
aqueous phase, with its monodispersity due to theon-treated and (right panel) treated with Apt-MNC; bars = 25 μm.
Figure 7 In vivo VEGFR2-targeting ability of Apt-MNC. (a) T2-
weighted MR images and their color map for VEGFR2-expressing
mouse model with intravenous injection of Apt-MNC or
carboxylated MNC (red line: brain tumor, red arrow: contrast
enhanced site). (b) Signal intensity graphs from T2-wieghted MR
images (*p < 0.01).
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itionally, negatively charged Apt-MNC surface repulsed
nonspecific binding on negatively charged cell surface,
increasing the aptamer-mediated specific binding on
VEGFR2 [21]. Thus, the characteristics of Apt-MNC
were suitable for a potential MR imaging probe to
detect the biomarker.
The prepared Apt-MNC exhibited a superpara-
magnetic property without magnetic hysteresis at zero
magnetic field, and the saturation magnetization value
was 98.8 emu g−1 Fe at 1.5 T. These magnetic properties
were highly acceptable as a sensitive MR imaging con-
trast agent (Figure 3a). The T2-weighted MR imaging of
Apt-MNC solution at various Fe concentrations was
obtained to evaluate the capability of imaging contrast
effect. The increase of Fe concentration accelerates
transverse relaxation to shorten the T2 relaxation time
(T2), resulting in a decreased signal intensity with dark
contrast. The T2 relaxation rate (R2 = 1/T2, s−1) was
plotted versus Fe concentration (mM) to determine the
relaxivity coefficient (r2) as 214.5 s−1 mM−1, which is
higher than that of commercial MR imaging contrast
agents (ferumoxide, 190.5 s−1 mM−1) (Figure 3b) [22].
To assess the biocompatibility of Apt-MNC, we inves-
tigated the in vitro cytotoxicity of carboxylated MNC
and Apt-MNC in U87MG cells by monitoring the effects
on cell viability and proliferation. Cell viabilities were
examined after incubation with various concentrations
of carboxylated MNC and Apt-MNC for 24 h. As shown
in Figure 4, U87MG cells treated with each MNC
solution showed no significant cytotoxicity effects even
at high concentration (up to 5 × 10−3 mg Fe/mL). These
results indicate that carboxylated MNC and Apt-MNC
are biocompatible for use as MR imaging probes.
To assess the in vitro VEGFR2-targeting ability of Apt-
MNC, VEGFR2-overexpressing PAE/KDR cells were
treated with Apt-fluorescein, and the cells were analyzed
by flow cytometry (Figure 5a). PAE/KDR cells treated
with Apt-fluorescein exhibited fluorescence levels of
76.8% (green) when compared with that of non-treated
PAE/KDR cells (control, 0.5% fluorescence level, black).
PAE/KDR cells treated with Apt-fluorescein were ana-
lyzed by confocal microscopy (Figure 5b). Cells exhibited
fluorescence in the nuclei (blue, DAPI) and in the cyto-
plasm (green, fluorescein); this confirmed that Apt could
effectively bind to VEGFR2 expressed on PAE/KDR cells.
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gated using dark-field microscopy. In Figure 6, the
scattered spots (yellow arrows) on PAE/KDR cells
treated with Apt-MNC were observed due to MNC.
However, carboxylate MNC without Apt conjugation
was not observed in non-treated PAE/KDR cells. These
results indicate that Apt-MNC effectively targeted
VEGFR2-expressing cells [19].
To investigate in vivo VEGFR2-targeting ability of Apt-
MNC using MR imaging, we prepared the glioblastoma-
bearing mouse xenograft model by intracranial injection
of U87MG cells into the brain. Although U87MG cancer
cells did not express VEGFR2, they induced extensive
VEGFR2 production through a tumor angiogenesis
pathway when transplanted into mouse brain [20]. MR
imaging for VEGFR2-expressing brain tumor was per-
formed before and after intravenous injection of Apt-
MNC and carboxylated MNC into the mouse tail vein
(200 μg Fe), and the color map images of Apt-MNC and
carboxylated MNC were presented to evaluate accurately
the contrast change (Figure 7a). Before the administration
of both MNC solutions (pre-injection), each T2-weighted
MR image of the tumor site appeared characteristically
bright with a low R2 value. Following injection of Apt-
MNC or carboxylated MNC (postinjection), we observed
that the tumor sites showed darkened images due to the
presence of magnetic components. However, the tumor
sites treated with Apt-MNC were darker than those
treated with carboxylated MNC (red arrow) because Apt-
MNC effectively targeted and bound to VEGFR2 of the
tumor tissue, whereas carboxylated MNC was washed out
in time [23-26]. In color map images, carboxylated MNC-Figure 8 Representative photographs of the brain stained with H & E
with H & E and Prussian blue after treated with Apt-MNC and carboxylated
(blue arrow).treated mouse showed no color change in whole brain re-
gion (blue or cyan), but Apt-MNC-treated mouse showed
significant color change in tumor site: violet (pre-injec-
tion) to green or red (postinjection). The MR imaging sig-
nal intensity (△R2/R2pre-injection; △R2 = R2 − R2pre-injection)
of Apt-MNC-treated tumor sites was strongly enhanced,
reaching a △R2/R2pre-injection value of 23.6% after the injec-
tion (Figure 7b). However, as expected, when carboxylated
MNC was administered to the mice, the △R2/R2pre-injection
values were 9.6% after injection, which were lower than
half of the Apt-MNC signal intensity (p < 0.01). These
MR imaging comparisons between Apt-MNC and carbo-
xylated MNC confirmed that Apt effectively targets
VEGFR2. Apt-MNC enabled the precise in vivo detection
of VEGFR2 expressed in the glioblastoma model using
MR imaging.
To determine the precise regions detected by Apt-
MNC, histological analysis was performed on the excised
brain after nanoprobe treatment and MR imaging
(Figure 8). The dark purple region in the H & E-stained
tissues clearly outlined the tumor (first column). The se-
lective accumulation of Apt-MNC within the tumor was
verified using the Prussian blue staining kit (second col-
umn; third column, magnified images). Ferric ions from
bound Apt-MNC in tumor tissue combined with the
ferrocyanide and resulted in the formation of a bright
blue pigment called Prussian blue (blue arrow). Tumor
tissues treated with carboxylated MNC showed red
(nuclei) and pink (cytoplasm) pigments, but lacked blue
pigment. These results demonstrated that the tumor
regions, which were identified in the in vivo MR
imaging, were successfully targeted by Apt-MNC.and Prussian blue. Representative photographs of the brain stained
MNC. Ferric ions from Apt-MNC showed bright blue pigment
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We described the development of smart VEGFR2-
targeting magnetic nanocrystal and evaluated its func-
tional capability as a biomarker-detecting nanoprobe
in vitro and in vivo. MNC was an ultrasensitive MR
imaging contrast agent. MNC was synthesized using the
thermal decomposition method, enveloped using biocom-
patible carboxyl polysorbate 80, and surface-modified
using a VEGFR2-targetable aptamer. Apt-MNC exhibited
a high magnetic resonance signal and efficient VEGFR2-
detecting ability with no cytotoxicity. Consequently, se-
lective targeting and high sensitivity in MR imaging
contributed to the advantageous features of Apt-MNC as
a novel VEGFR2-targeting nanoprobe. Furthermore, the
incorporation of therapeutic agents in Apt-MNC might
provide outstanding designs and applications for future
clinical nanoprobes.
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